PMID- 25012943
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 56
IP  - 4
DP  - 2015 Apr
TI  - Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell 
      lymphoma.
PG  - 993-8
LID - 10.3109/10428194.2014.941835 [doi]
AB  - Platelet derived growth factor-alpha (PDGFR-alpha) is expressed in peripheral T cell 
      lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in 
      vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of 
      imatinib in 12 patients with relapsed or refractory T-cell non-Hodgkin lymphoma 
      (T-NHL). PDGFR-alpha expression by immunohistochemistry and fluorescence in situ 
      hybridization (FISH) to assess for FIP1L1-PDGFR-alpha fusion and/or PDGFR-alpha 
      amplification were not required for study entry. We documented no objective 
      responses. The median progression-free survival was 21.0 days (90% confidence 
      interval [CI] 15.0, 28.0) and median overall survival was 154 days (90% CI 35, 
      242). Four patients had tissue available for analysis of PDGFR-alpha by 
      immunohistochemistry and three of these patients' tumors expressed PDGFR-alpha. 
      Imatinib was not effective for the treatment of peripheral T cell lymphoma in an 
      unselected group of patients in which PDGFR-alpha expression was not required for 
      study entry.
FAU - Jacobsen, Eric
AU  - Jacobsen E
AD  - Medical Oncology, Dana-Farber Cancer Institute , Boston, MA , USA.
FAU - Pozdnyakova, Olga
AU  - Pozdnyakova O
FAU - Redd, Robert
AU  - Redd R
FAU - Fisher, David C
AU  - Fisher DC
FAU - Dorfman, David M
AU  - Dorfman DM
FAU - Dal Cin, Paola
AU  - Dal Cin P
FAU - LaCasce, Ann
AU  - LaCasce A
FAU - Armand, Philippe
AU  - Armand P
FAU - Hochberg, Ephraim
AU  - Hochberg E
FAU - Cote, Gregory
AU  - Cote G
FAU - Shahsafaei, Ali
AU  - Shahsafaei A
FAU - Neuberg, Donna
AU  - Neuberg D
FAU - Brown, Jennifer R
AU  - Brown JR
FAU - Freedman, Arnold S
AU  - Freedman AS
LA  - eng
SI  - ClinicalTrials.gov/NCT00684411
PT  - Clinical Trial
PT  - Journal Article
DEP - 20140820
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (mRNA Cleavage and Polyadenylation Factors)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.1 (FIP1L1-PDGFRA fusion protein, human)
RN  - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Disease-Free Survival
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Imatinib Mesylate/*therapeutic use
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, T-Cell, Peripheral/*drug therapy/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/genetics/metabolism
MH  - Receptor, Platelet-Derived Growth Factor alpha/genetics/metabolism
MH  - Recurrence
MH  - Treatment Outcome
MH  - mRNA Cleavage and Polyadenylation Factors/genetics/metabolism
OTO - NOTNLM
OT  - Lymphoma
OT  - PDGFR-alpha
OT  - imatinib
EDAT- 2014/07/12 06:00
MHDA- 2016/04/05 06:00
CRDT- 2014/07/12 06:00
PHST- 2014/07/12 06:00 [entrez]
PHST- 2014/07/12 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.3109/10428194.2014.941835 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2015 Apr;56(4):993-8. doi: 10.3109/10428194.2014.941835. Epub 2014 
      Aug 20.